This ppt presentation shows the role of incretins in Glucose Regulation in Type 2 Diabetes. One of the key mechanisms underlying the development of T2DM is the dysfunction of the incretin system, which regulates glucose homeostasis through the secretion of gut hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

1. The Role of
Incretins in
Glucose
Regulation in
Type 2 Diabetes

2. Agenda

3. Introduction

4. Incretins

5. Mechanism

6. Function of GLP-1 Function of GIP

7. Incretins & Blood Glucose

8. Incretins & Blood Glucose

9. Challenges

10. Overcoming the Challenges
.

12. Why the Need?
Hypoglycemia: Many antidiabetic drugs can cause low blood sugar levels,
which can be dangerous if left untreated. Symptoms of hypoglycemia
include sweating, shaking, confusion, and loss of consciousness.
Weight gain: Some antidiabetic drugs can cause weight gain, which can
be a concern for people who are already overweight or obese.
Cardiovascular risks: Four out of five classes of antidiabetic drugs have
been associated with an increased risk of cardiovascular events, such as
heart attacks or strokes.
Kidney damage: Some antidiabetic drugs can cause kidney damage,
especially if used for a prolonged period of time.

13. Who should take?

14. Side effects
1.Nausea
and vomiting
1.Diarrhea or
constipation
1.Abdominal
pain or
discomfort
1.Loss of
appetite
1.Headache
1.Dizziness 1.Fatigue
1.Pancreatitis
(inflammation of
the pancreas)
1.Gallbladde
r problems

15. Conclusion
• Incretins, such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-
dependent insulinotropic peptide), are important hormones that play a
key role in glucose metabolism and insulin secretion.
• GLP-1 receptor agonists have become an important class of
medications for the management of type 2 diabetes. They have been
shown to improve glycemic control, reduce body weight, and lower the
risk of cardiovascular events. Additionally, GLP-1 receptor agonists
have a low risk of causing hypoglycemia, and they may also be used in
the treatment of obesity.
• The availability of both injectable and oral forms of GLP-1 receptor
agonists provides patients with options for their diabetes treatment.
While GLP-1 receptor agonists do have some common side effects,
their benefits for glycemic control and overall cardiovascular health
make them an attractive option for many people with type 2 diabetes.

16. Thank You
Rajat Kumar
razatsaini@gmail.com
M. Pharma (Pharmacology)
Gurukul Kangri (Deemed to be
University

17. References
https://doi.org/10.3389/fendo.2019.00260

18. References